Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: A subanalysis of the Empa-reg Outcome trial

Diabetes Care

Volumn 42, Issue 3, 2019, Pages E42-E44

  Verma, Subodh ^a   David Mazer, C ^a   Bhatt, Deepak L ^b   Raj, Satish R ^c,d   Yan, Andrew T ^a   Verma, Atul ^a   Ferrannini, Ele ^e   Simons, Gudrun ^f   Lee, Jisoo ^f   Zinman, Bernard ^g   George, Jyothis T ^f   Fitchett, David ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^g MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; HEMOGLOBIN A1C; PLACEBO;

AGE; ALL CAUSE MORTALITY; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG EFFECT; ELECTROCARDIOGRAM; ESTIMATED GLOMERULAR FILTRATION RATE; GENDER; GLYCEMIC CONTROL; HAZARD RATIO; HEALTH CARE QUALITY; HEART DEATH; HEART LEFT VENTRICLE HYPERTROPHY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; TREATMENT OUTCOME;

EID: 85061917506     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc18-1959     Document Type: Article

References (5)

1. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014;57: 660–671
2. Seferović PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 2015;36:1718–1727, 1727a–1727c
3. Bhatt DL, James GD, Pickering TG, Devereux RB. Relation of arterial pressure level and variability to left ventricular geometry in normo-tensive and hypertensive adults. Blood Press Monit 1996;1:415–424
4. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128
5. Verma S, McMurray JJV, Cherney DZI. The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol 2017;2:939–940